文献速递炎症性肠病

系统综述与网络Meta分析:炎症性肠病中生物制剂与小分子药物带状疱疹感染风险

Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-31

该系统综述与网络Meta分析检索截至2022年10月4日的文献,纳入25项随机对照试验(9935例患者),评估炎症性肠病获批生物制剂与小分子药物的带状疱疹风险。结果显示,仅托法替布10 mg每日两次(RR=6.90;95%CI 1.56-30.63,NNH=97;95%CI 19-1022)和乌帕替尼45 mg每日一次(RR=7.89;95%CI 1.04-59.59,NNH=83;95%CI 10-14,305)显著增加带状疱疹感染风险。Janus激酶抑制剂最可能增加感染风险,且风险随剂量升高而增加。

要点

  • 仅托法替布10 mg每日两次和乌帕替尼45 mg每日一次显著增加带状疱疹风险。
  • Janus激酶抑制剂类最可能增加带状疱疹感染风险。
  • Janus激酶抑制剂带状疱疹风险随剂量升高而增加。

核心结论

  • 网络Meta分析显示,Janus激酶抑制剂托法替布及Janus激酶抑制剂类药物最可能增加带状疱疹感染风险。
  • 带状疱疹感染风险随Janus激酶抑制剂剂量升高而增加。

研究设计与样本

  • 系统综述与网络Meta分析,检索截至2022年10月4日的文献,纳入25项在腔内克罗恩病或溃疡性结肠炎中评估这些药物的随机对照试验(9935例患者)。
  • 采用频率学方法与随机效应模型,合并数据以相对风险(RR)及95%置信区间(CI)表示。

主要发现

  • 仅托法替布10 mg每日两次(RR=6.90;95%CI 1.56-30.63,NNH=97;95%CI 19-1022)和乌帕替尼45 mg每日一次(RR=7.89;95%CI 1.04-59.59,NNH=83;95%CI 10-14,305)显著增加带状疱疹感染风险。
  • Janus激酶抑制剂最可能增加感染风险,最低剂量RR=3.16(95%CI 1.02-9.84,NNH=265;95%CI 65-28,610),较高剂量RR=5.91(95%CI 2.21-15.82,NNH=117;95%CI 39-473)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologics and small molecules for inflammatory bowel disease (IBD) may increase infection risk. Herpes zoster causes acute and long-term symptoms, but vaccination is not recommended in patients with IBD, unless >50 years of age. AIMS: To examine risk of Herpes zoster infection with all licensed biologics and small molecules for IBD using network meta-analysis. METHODS: We searched the literature to 4th October 2022, for randomised controlled trials of these drugs in luminal Crohn's disease or ulcerative colitis reporting data on occurrence of Herpes zoster infection during follow-up. We used a frequentist approach and a random effects model, pooling data as relative risks (RRs) with 95% confidence intervals (CIs). RESULTS: We identified 25 trials (9935 patients). Only tofacitinib 10 mg b.d. (RR = 6.90; 95% CI 1.56-30.63, number needed to harm (NNH) = 97; 95% CI 19-1022) and upadacitinib 45 mg o.d. (RR = 7.89; 95% CI 1.04-59.59, NNH = 83; 95% CI 10-14,305) were significantly more likely to increase risk of Herpes zoster infection. Janus kinase inhibitors were the most likely drug class to increase risk of infection, and risk increased with higher doses (RR with lowest dose = 3.16; 95% CI 1.02-9.84, NNH = 265; 95% CI 65-28,610, RR with higher dose = 5.91; 95% CI 2.21-15.82, NNH = 117; 95% CI 39-473). CONCLUSIONS: In a network meta-analysis, the janus kinase inhibitor tofacitinib, and all janus kinase inhibitors considered as a class, were most likely to increase risk of Herpes zoster infection. Risk increased with higher doses.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Din S, Selinger CP, Black CJ, et al. Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease. Aliment Pharmacol Ther. 2022. PMID: 36585944. doi:10.1111/apt.17379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。